Treats hyperkalemia. ANDA 40028, held by Ani Pharms. Sodium Polystyrene Sulfonate.
As of Nov 16, 2026, ANDA 40028 (Kionex), held by Ani Pharms, was first approved by FDA on Sep 17, 2007, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Kionex Suspension is indicated for the treatment of hyperkalemia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 17, 2007 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Kionex15GM/60ML · suspension;oral, rectal | Sodium Polystyrene Sulfonate | Rx |
| May 3, 2024 | Supplement 19Manufacturing | Approved | None posted |
| Oct 18, 2022 | Supplement 14Labeling · Standard review | Approved | None posted |
| Apr 26, 2015 | Supplement 12Labeling | Approved | None posted |
| Sep 17, 2007 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters